CDT logo

CDT CDT Equity Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$0.80
-0.04 (-4.29%)

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the trea…

Market Cap: $616.7Kwww.cdtequity.com

Price

No data yet.

Social Signal Score

37
5d
—
30d
40
4 mentions
—
60d
36
7 mentions
—
90d
36
7 mentions
—
news: 7

Revenue

$750.16M
$0.00$250.05M$500.10M$750.16M
Dec 2021Jun 2026

Company Profile

CEO
Jamie Bligh
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
1.56
Country
US
Piotroski score
7 / 9 (Strong)
Altman Z-score
1.44
www.cdtequity.com